dansylarginine n-(3-ethyl-1,5-pentanediyl)amide has been researched along with fibrinopeptide a in 1 studies
Studies (dansylarginine n-(3-ethyl-1,5-pentanediyl)amide) | Trials (dansylarginine n-(3-ethyl-1,5-pentanediyl)amide) | Recent Studies (post-2010) (dansylarginine n-(3-ethyl-1,5-pentanediyl)amide) | Studies (fibrinopeptide a) | Trials (fibrinopeptide a) | Recent Studies (post-2010) (fibrinopeptide a) |
---|---|---|---|---|---|
32 | 0 | 0 | 1,336 | 104 | 50 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boissel, JP; Elion, J; Jandrot-Perrus, M; Josso, F; Rabiet, MJ | 1 |
1 other study(ies) available for dansylarginine n-(3-ethyl-1,5-pentanediyl)amide and fibrinopeptide a
Article | Year |
---|---|
Thrombin Metz: characterization of the dysfunctional thrombin derived from a variant of human prothrombin.
Topics: Antithrombin III; Arginine; Blood Coagulation; Dansyl Compounds; Enzyme Activation; Fibrinopeptide A; Fibrinopeptide B; Heparin; Humans; Hypoprothrombinemias; Kinetics; Platelet Aggregation; Prothrombin; Thrombin | 1984 |